Background Lichen planus is a chronic, non-infectious inflammatory disease that affects the skin and mucous membranes, including the oral cavity (OLP). Symptomatic forms cause burning and pain which can impact the patient's quality of life. The zinc-L-carnosine complex contained in Hepilor mouthwash has the ability to heal damaged mucous membranes. Aim of the study The aim of this study is to evaluate the efficacy of Hepilor mouthwash, which contains Zinco-L-Carnosine molecule, in the treatment of the painful symptoms caused by OLP. Materials and methods The inclusion criteria were symptomatic patients with a clinical and histological diagnosis of OLP. The exclusion criteria were asymptomatic patients, patients who had received other treatments such as corticosteroids, antifungals or laser photobiomodulation in the last 3 months, and patients with clinical signs of oral candidiasis. This study evaluated a single group of patients exposed in a crossover design to two distinct treatments (first A then B), which could include Hepilor mouthwash or placebo, randomly assigned. The verum and placebo groups from phase 1 are switched in phase 2 of the study Patient discomfort was assessed using the VAS-D scale and the "Oral Lichen Planus Symptom Severity Measure (LPOSSM)". Results VAS scores decreased in the verum groups, but not significantly. Conclusions The selection of a larger sample, the standardization of subjective evaluation methods and a different statistical approach not based on normality would probably allow a more solid relationship to be established between the hypothesis and the efficacy of the treatment.
Introduzione Il Lichen Planus è una malattia infiammatoria cronica non infettiva che colpisce cute e mucose, tra cui quella orale (OLP). Le forme sintomatiche comportano bruciore e dolore tali da pregiudicare la qualità di vita del paziente. Il complesso zinco-L-carnosina contenuto in Hepilor collutorio presenta capacità di guarigione delle mucose danneggiate. Scopo dello studio L’obiettivo di questo studio è quello di valutare l’efficacia di Hepilor collutorio a base di Zinco-L-Carnosina nel trattamento della sintomatologia algica causata dal OLP. Materiali e metodi I criteri di inclusione sono pazienti sintomatici con diagnosi clinica e istologica di OLP. I criteri di esclusione sono pazienti asintomatici, pazienti che hanno ricevuto altri trattamenti come corticosteroidi, antimicotici o fotobiomodulazione laser negli ultimi 3 mesi e pazienti che hanno evidenti segni clinici di candidosi orale. Questo studio valuta un singolo gruppo di pazienti esposti in un disegno crossover a due trattamenti distinti (prima A poi B), che possono includere collutorio Hepilor o placebo, assegnati in maniera randomizzata. Quindi i gruppi verum e placebo della fase 1 si invertono nella fase 2 dello studio. Il disagio dei pazienti viene valutato in base alla scala VAS-D e alla "Oral Lichen Planus Symptom Severity Measure (LPOSSM)". Risultati I punteggi di VAS sono diminuiti nei gruppi verum, ma non in maniera statisticamente significativa. Conclusioni La selezione di un campione più ampio, la standardizzazione dei metodi di valutazione soggettiva e il diverso approccio statistico non basato sulla normalità consentirebbero probabilmente di stabilire una relazione più solida tra l'ipotesi in esame e l'efficacia del trattamento.
Efficacia di Zinco-L-Carnosina nel trattamento del Lichen Planus Orale
BERTI, ALISSA
2023/2024
Abstract
Background Lichen planus is a chronic, non-infectious inflammatory disease that affects the skin and mucous membranes, including the oral cavity (OLP). Symptomatic forms cause burning and pain which can impact the patient's quality of life. The zinc-L-carnosine complex contained in Hepilor mouthwash has the ability to heal damaged mucous membranes. Aim of the study The aim of this study is to evaluate the efficacy of Hepilor mouthwash, which contains Zinco-L-Carnosine molecule, in the treatment of the painful symptoms caused by OLP. Materials and methods The inclusion criteria were symptomatic patients with a clinical and histological diagnosis of OLP. The exclusion criteria were asymptomatic patients, patients who had received other treatments such as corticosteroids, antifungals or laser photobiomodulation in the last 3 months, and patients with clinical signs of oral candidiasis. This study evaluated a single group of patients exposed in a crossover design to two distinct treatments (first A then B), which could include Hepilor mouthwash or placebo, randomly assigned. The verum and placebo groups from phase 1 are switched in phase 2 of the study Patient discomfort was assessed using the VAS-D scale and the "Oral Lichen Planus Symptom Severity Measure (LPOSSM)". Results VAS scores decreased in the verum groups, but not significantly. Conclusions The selection of a larger sample, the standardization of subjective evaluation methods and a different statistical approach not based on normality would probably allow a more solid relationship to be established between the hypothesis and the efficacy of the treatment.File | Dimensione | Formato | |
---|---|---|---|
Berti_Alissa.pdf
accesso riservato
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/69142